Sulindac and its metabolites inhibit multiple transport proteins in rat and human hepatocytes

Journal of Pharmacology and Experimental Therapeutics

Volumn 334, Issue 2, 2010, Pages 410-418

  Lee, Jin Kyung ^a   Paine, Mary F ^a   Brouwer, Kim L R ^a  

^a University of North Carolina   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BILE ACID; BREAST CANCER RESISTANCE PROTEIN; CARRIER PROTEIN; DRUG METABOLITE; ESTRADIOL 17 BETA GLUCURONIDE; GLUCURONIDE; NITROFURANTOIN; SULINDAC; SULINDAC SULFIDE; SULINDAC SULFONE; TAUROCHOLIC ACID; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BILIARY EXCRETION; CELL CULTURE; CONTROLLED STUDY; DRUG EFFECT; DRUG TRANSPORT; HUMAN; HUMAN CELL; HYPOTHESIS; IN VITRO STUDY; LIVER CELL; LIVER INJURY; LIVER TOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; RAT;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CARRIER PROTEINS; CELLS, CULTURED; ESTRADIOL; HEPATOCYTES; HUMANS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NITROFURANTOIN; ORGANIC ANION TRANSPORTERS; RATS; SULINDAC; TAUROCHOLIC ACID;

EID: 77954942949     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.110.165852     Document Type: Article

References (35)

1. Aithal GP and Day CP (2007) Nonsteroidal anti-inflammatory drug-induced hepatotoxicity. Clin Liver Dis 11:563-575, vi-vii.
2. 3H]estradiol-17 β(β-D-glucuronide) in isolated rat hepatocytes. Mol Pharmacol 32:519-523.
3. 50) of an enzymatic reaction. Biochem Pharmacol 22:3099-3108.
4. Davies B and Morris T (1993) Physiological parameters in laboratory animals and humans. Pharm Res 10:1093-1095.
5. Dobrinska MR, Furst DE, Spiegel T, Vincek WC, Tompkins R, Duggan DE, Davies RO, and Paulus HE (1983) Biliary secretion of sulindac and metabolites in man. Biopharm Drug Dispos 4:347-358. (Pubitemid 14243007)
6. Duggan DE, Hooke KF, Noll RM, Hucker HB, and Van Arman CG (1978) Comparative disposition of sulindac and metabolites in five species. Biochem Pharmacol 27:2311-2320.
7. Dujovne CA, Pitterman A, Vincek WC, Dobrinska MR, Davies RO, and Duggan DE (1983) Enterohepatic circulation of sulindac and metabolites. Clin Pharmacol Ther 33:172-177.
8. El-Sheikh AA, van den Heuvel JJ, Koenderink JB, and Russel FG (2007) Interaction of nonsteroidal anti-inflammatory drugs with multidrug resistance protein (MRP) 2/ABCC2- and MRP4/ABCC4-mediated methotrexate transport. J Pharmacol Exp Ther 320:229-235.
9. Fattinger K, Funk C, Pantze M, Weber C, Reichen J, Stieger B, and Meier PJ (2001) The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions. Clin Pharmacol Ther 69:223-231.
10. Funk C, Pantze M, Jehle L, Ponelle C, Scheuermann G, Lazendic M, and Gasser R (2001) Troglitazone-induced intrahepatic cholestasis by an interference with the hepatobiliary export of bile acids in male and female rats. Correlation with the gender difference in troglitazone sulfate formation and the inhibition of the canalicular bile salt export pump (Bsep) by troglitazone and troglitazone sulfate. Toxicology 167:83-98.
11. Furst DE, Herman RA, Koehnke R, Ericksen N, Hash L, Riggs CE, Porras A, and Veng-Pedersen P (1990) Effect of aspirin and sulindac on methotrexate clearance. J Pharm Sci 79:782-786.
12. Hamman MA, Haehner-Daniels BD, Wrighton SA, Rettie AE, and Hall SD (2000) Stereoselective sulfoxidation of sulindac sulfide by flavin-containing monooxygenases. Comparison of human liver and kidney microsomes and mammalian enzymes. Biochem Pharmacol 60:7-17.
13. Huang SM, Strong JM, Zhang L, Reynolds KS, Nallani S, Temple R, Abraham S, Habet SA, Baweja RK, Burckart GJ, et al. (2008) New era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process. J Clin Pharmacol 48:662-670.
14. Imai Y, Nakane M, Kage K, Tsukahara S, Ishikawa E, Tsuruo T, Miki Y, and Sugimoto Y (2002) C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance. Mol Cancer Ther 1:611-616.
15. Ito K, Iwatsubo T, Kanamitsu S, Ueda K, Suzuki H, and Sugiyama Y (1998) Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver. Pharmacol Rev 50:387-412.
16. Kemp DC, Zamek-Gliszczynski MJ, and Brouwer KLR (2005) Xenobiotics inhibit hepatic uptake and biliary excretion of taurocholate in rat hepatocytes. Toxicol Sci 83:207-214.
17. Khamdang S, Takeda M, Noshiro R, Narikawa S, Enomoto A, Anzai N, Piyachaturawat P, and Endou H (2002) Interactions of human organic anion transporters and human organic cation transporters with nonsteroidal anti-inflammatory drugs. J Pharmacol Exp Ther 303:534-539. (Pubitemid 35231223)
18. Kosters A and Karpen SJ (2008) Bile acid transporters in health and disease. Xenobiotica 38:1043-1071.
19. Kouzuki H, Suzuki H, Ito K, Ohashi R, and Sugiyama Y (1998) Contribution of sodium taurocholate cotransporting polypeptide to the uptake of its possible substrates into rat hepatocytes. J Pharmacol Exp Ther 286:1043-1050. (Pubitemid 29003502)
20. Kouzuki H, Suzuki H, Ito K, Ohashi R, and Sugiyama Y (1999) Contribution of organic anion transporting polypeptide to uptake of its possible substrates into rat hepatocytes. J Pharmacol Exp Ther 288:627-634.
21. Laffi G, La Villa G, Pinzani M, Ciabattoni G, Patrignani P, Mannelli M, Cominelli F, and Gentilini P (1986) Altered renal and platelet arachidonic acid metabolism in cirrhosis. Gastroenterology 90:274-282.
22. Lee JK, Marion TL, Abe K, Lim C, Pollock GM, and Brouwer KLR (2010) Hepatobiliary disposition of troglitazone and metabolites in rat and human sandwichcultured hepatocytes: use of Monte Carlo simulations to assess the impact of changes in biliary excretion on troglitazone sulfate accumulation. J Pharmacol Exp Ther 332:26-34.
23. +-dependent taurocholate cotransporting polypeptide (NTCP/ SLC10A1) by bosentan: a mechanism for species differences in hepatotoxicity. J Pharmacol Exp Ther 321:1170-1178.
24. Li N, Bi YA, Duignan DB, and Lai Y (2009) Quantitative expression profile of hepatobiliary transporters in sandwich cultured rat and human hepatocytes. Mol Pharm 6:1180-1189.
25. 2+ modulation to evaluate biliary excretion in sandwich-cultured rat hepatocytes. J Pharmacol Exp Ther 289:1592-1599.
26. Morisaki K, Robey RW, Ozvegy-Laczka C, Honjo Y, Polgar O, Steadman K, Sarkadi B, and Bates SE (2005) Single nucleotide polymorphisms modify the transporter activity of ABCG2. Cancer Chemother Pharmacol 56:161-172.
27. Rius M, Nies AT, Hummel-Eisenbeiss J, Jedlitschky G, and Keppler D (2003) Cotransport of reduced glutathione with bile salts by MRP4 (ABCC4) localized to the basolateral hepatocyte membrane. Hepatology 38:374-384.
28. Shitara Y, Li AP, Kato Y, Lu C, Ito K, Itoh T, and Sugiyama Y (2003) Function of uptake transporters for taurocholate and estradiol 17β-D-glucuronide in cryopreserved human hepatocytes. Drug Metab Pharmacokinet 18:33-41.
29. Sugiyama D, Kusuhara H, Shitara Y, Abe T, Meier PJ, Sekine T, Endou H, Suzuki H, and Sugiyama Y (2001) Characterization of the efflux transport of 17β-estradiol-D-17β-glucuronide from the brain across the blood-brain barrier. J Pharmacol Exp Ther 298:316-322. (Pubitemid 32574542)
30. Tarazi EM, Harter JG, Zimmerman HJ, Ishak KG, and Eaton RA (1993) Sulindacassociated hepatic injury: analysis of 91 cases reported to the Food and Drug Administration. Gastroenterology 104:569-574.
31. Tatsumi K, Kitamura S, and Yamada H (1983) Sulfoxide reductase activity of liver aldehyde oxidase. Biochim Biophys Acta 747:86-92.
32. Wilson ZE, Rostami-Hodjegan A, Burn JL, Tooley A, Boyle J, Ellis SW, and Tucker GT (2003) Inter-individual variability in levels of human microsomal protein and hepatocellularity per gram of liver. Br J Clin Pharmacol 56:433-440.
33. Yamasaki Y, Ieiri I, Kusuhara H, Sasaki T, Kimura M, Tabuchi H, Ando Y, Irie S, Ware J, Nakai Y, et al. (2008) Pharmacogenetic characterization of sulfasalazine disposition based on NAT2 and ABCG2 (BCRP) gene polymorphisms in humans. Clin Pharmacol Ther 84:95-103.
34. Yue W, Abe K, and Brouwer KLR (2009) Knocking down breast cancer resistance protein (Bcrp) by adenoviral vector-mediated RNA interference (RNAi) in sandwich- cultured rat hepatocytes: a novel tool to assess the contribution of Bcrp to drug biliary excretion. Mol Pharm 6:134-143.
35. Zhang W, Yu BN, He YJ, Fan L, Li Q, Liu ZQ, Wang A, Liu YL, Tan ZR, Fen J, et al. (2006) Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males. Clin Chim Acta 373:99-103.